<DOC>
	<DOCNO>NCT01606215</DOCNO>
	<brief_summary>This randomise , double-blind crossover study study effect intravenous treatment autologous ( derived individual ) mesenchymal stem cell ( MSCs ) patient multiple sclerosis ( MS ) . Current treatment MS target immune system curative . There much interest MSCs potential affect immune system may also promote repair . This study use MSCs harvest bone marrow grown 52 day give back person harvest . This avoids chemotherapy therefore safer type stem cell . In crossover study , everyone receive stem cell back half delayed 24 week . The primary outcome check procedure safe measure change MRI 24 week . Other exploratory measure try assess effect repair central nervous system ( CNS ) .</brief_summary>
	<brief_title>Stem Cells Rapidly Evolving Active Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Patients clinically radiologically active multiple sclerosis define : 1 . Diagnosis MS : Relapsing remit MS ( RRMS ) : ≥ 1 moderatesevere relapse ≥1 GEL past 18 month ≥ 1 moderatesevere relapse ≥1 new T2 lesion past 18 month . Secondary progressive MS ( SPMS ) increase ≥ 1 EDSS point ( baseline EDSS ≤ 5 ) 0.5 EDSS point ( baseline EDSS ≥ 5.5 ) , previous 18 month ≥ 1 GEL past 18 month ≥ 1 moderatesevere relapse ≥1 new T2 lesion past 18 month . Primary progressive MS ( PPMS ) patient positive oligoclonal band ( OCBs ) cerebrospinal fluid ( CSF ) increase ≥ 1 EDSS point ( baseline EDSS ≤ 5.0 ) 0.5 EDSS point ( baseline EDSS ≥ 5.5 ) , quantifiable , objective evidence equivalent progression previous 18 month ≥ 1 GEL past 18 month ≥ 1 new T2 lesion past 18 month . 2 . Age 18 50 year . 3 . Disease duration 2 10 year diagnosis ( inclusive ) . 4 . Expanded Disability Status Scale ( EDSS ) 3.0 6.5 screening evaluation . 5 . ≥ 1 GEL MRI within 6 month prior harvest . 6 . Adequate culture subject 's MSCs release clinical use . 1 . RRMS without least one severe relapse previous 18 month without least one GEL one new T2 previous 18 month . 2 . SPMS without relapse without new lesion ( GEL T2 positive ) MRI last 18 month . 3 . PPMS without positive CSF OCBs without GEL new T2 lesion previous 18 month . 4 . No gadolinium enhance lesion ( ) 3 month prior bone marrow harvesting . 5 . A previously ineligible patient fail meet MRI requirement inclusion criterion review even image , reveal ≥ 1 GEL , become available . 6 . Failure bone marrow ( BM ) sample generate MSCs suitable clinical use within specified time frame ( 4 week ) . 7 . Treatment immunosuppressive therapy , include natalizumab fingolimod , within last 3 month . 8 . Treatment interferonbeta glatiramer acetate within last 1 month . 9 . Treatment alemtuzumab ( campath1H ) within last 2 year . 10 . Prior treatment total lymphoid irradiation autologous allogeneic hematopoietic stem cell transplantation . 11 . Participation clinical trial experimental drug 6 month study entry . 12 . Corticosteroid treatment last 30 day . 13 . Presence active chronic infection . 14 . Previous history malignancy basal cell carcinoma skin carcinoma situ remission one year . 15 . Severely limited life expectancy comorbid illness . 16 . Abnormal blood count , history myelodysplasia cytopenia . 17 . Known pregnancy , positive urine pregnancy test screening risk pregnancy ( include patient unwilling practice active contraception duration study ) . 18 . Contraindication MRI include limited intracranial aneurysm clip ( except Sugita ) , history intraorbital metal fragment remove MD ( confirm orbital XRay ) , pacemaker nonMRI compatible device ( e.g . heart valve , inner ear implant ) , history claustrophobia inability subject lie still back period 1.5 hour MRI scanner . 19 . An estimated glomerular filtration rate ( eGFR ) &lt; 60 mL/min/1.73m2 history presence renal impairment ( e.g . serum creatinine clearance le 30ml/min ) . 20 . Inability give write informed consent/comply study procedure . 21 . Any significant organ dysfunction comorbidity Investigators consider would put subject unacceptable risk participate study would interfere functional assessment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>multiple sclerosis</keyword>
	<keyword>mesenchymal stem cell</keyword>
	<keyword>bone marrow</keyword>
	<keyword>rapidly evolve</keyword>
</DOC>